[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2007-02-01 / Cir Esp 2007 Feb;81(2):82-6Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis
/in Dendritic Cells, Hyperthermia, International Publications /von 2007-01-19 / Cancer Gene Ther. 2007 Apr;14(4):409-20Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics
/in Glioblastoma, International Publications /von 2007-01-15 / Clin. Cancer Res. 2007 Jan;13(2 Pt 1):566-575Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
/in International Publications, Newcastle Disease Virus /von 2007-01-15 / Cancer Res. 2007 Jan;67(2):429-32p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2007-01-10 / J. Virol. 2007 Mar;81(6):2817-30Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells
/in International Publications, Malignant Melanoma /von 2007-01-08 / Vet. J. 2008 Jan;175(1):126-9Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells
/in Breast Cancer, International Publications /von 2007-01-03 / Vaccine 2007 Mar;25(14):2610-9Immunological role of dendritic cells in cervical cancer
/in Cervical Cancer, Dendritic Cells, International Publications /von 2007-01-01 / Adv. Exp. Med. Biol. 2007;601:155-62Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response
/in Colorectal Cancer, International Publications /von 2007-01-01 / Folia Histochem. Cytobiol. 2007;45(4):349-55
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de